Keywords
Direct Medical Costs
Outpatient
How to Cite
Abstract
Background : Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from abnormalities in insulin secretion or action. The high prevalence of type 2 DM has become a major global health concern, necessitating economic evaluations to assess the cost burden of treatment. Purpose: This study aimed to analyze the direct medical costs associated with outpatient management of type 2 DM at Mustika Medika Hospital. Method: A descriptive, retrospective design was employed using medical record data of patients treated between January and December 2020. Results: The results showed that the average direct medical costs were IDR 410,429 for glimepiride, IDR 393,130 for metformin, IDR 281,700 for acarbose, and IDR 628,065 for combination therapy with metformin and glimepiride. The highest cost was observed in combination therapy (IDR 628,065), whereas the lowest cost was associated with acarbose therapy (IDR 281,700). Conclusion: These findings provide valuable insights into the economic aspects of type 2 DM pharmacotherapy, which may support healthcare providers and policymakers in optimizing treatment strategies.
References
Aisyah, T. M. (2006). Cost analysis Of Diabetes mellitus therapy In Dr. Sardjito Hospital Yogyakarta. Indonesian Journal of Pharmacy, 17(Vol 17 No 3, 2006),130–135.
Andayani, T. M. (2013). Farmakoekonomi Prinsip Dan Metodologi. Bursa Ilmu.
Depkes, R. (2010). Profil Kesehatan Republik Indonesia.
Dyah, R. I., Wahyono, D., & Andayani, T. M. (2014). Analisis Biaya Terapi Pasien Diabetes Melitus Rawat Inap. Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 4(1), 55–62. https://doi.org/10.22146/jmpf.257
Finkelstein, E. A., Chay, J., & Bajpai, S. (2014). The economic burden of self-reported and undiagnosed cardiovascular diseases and diabetes on Indonesian households. PLoS ONE, 9(6). https://doi.org/10.1371/journal.pone.0099572
Hongdiyanto, A., Yamlean, P. V. Y., & Supriati, S. (2014). Evaluasi Kerasionalan Pengobatan Diabetes Melitus Tipe 2 Pada Pasien Rawat Inap Di Rsup Prof. Dr. R. D. Kandou Manado Tahun 2013. Pharmacon, 3(2), 77–87. https://doi.org/10.35799/pha.3.2014.4775
Istiqomatunnisa. (2014). Rasionalitas Penggunaan Obat Anti Diabetes Dan Evaluasi Beban Biaya Perbekalan Farmasi Pada Pasien Rawat Inap Kartu Jakarta Sehat Di Rumah Sakit Tni Angkatan Laut Dr. Mintohardjo.
Kemenkes Ri. (2013). Pedoman Surveilans Penyakit Tidak Menular Kementerian Kesehatan Ri. 1–31.
Khairinnisa, A., Ysmaini, H., & Hadiwirjo, Y. H. (2020). Perbandingan Penggunaan Glibenclamid-Metformin dan Glimepirid-Metformin Terhadap Efek Samping Hipoglikemia Pasien Diabetes Melitus Tipe-2 di Kota Tangerang Selatan Bulan Januari–Oktober Tahun 2019. Seminar Nasional Riset Kedokteran, 4(2), 147–154.
Furdiyanti, N. H., Luhurningtyas, F. P., Ratna, S., & Yulianti. (2017). Evaluasi Dosis Dan Interaksi Obat Antidiabetika Oral Pada Pasien Diabetes Mellitus Tipe Ii Evaluation Of Oral Antidiabetic Dosing And Drug Interactions In Type Ii Diabetic Patients. 7(Dm), 191–196.
Kumala Swandari, M. T., Maryanti, D., A’yuni, Q., & Calista Cahyani, D. (2018). Jurnal Ilmiah Kefarmasian. 64–68.
Notoatmodjo, S. (2012). Metodologi Penelitian Kesehatan Hlm: 1-236. Rineka Cipta.
Perkeni. (2015). Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. Perkumpulan Endokrinologi Indonesia, 1–117.
Prasetyani, D. (2017). Analisis Faktor Yang Mempengaruhi Kejadian Diabetes Melitus (Dm) Tipe 2. Analisis Faktor Yang Mempengaruhi Kejadian Diabetes Miletus Tipe 2, 2(2), 1–9.
Rasdianah, N., & Gani, A. S. W. (2021). Interaksi Obat Pada Pasien Diabetes
Melitus Tipe 2 Dengan Penyakit Penyerta Di Rumah Sakit Otanaha Kota Gorontalo. Indonesian Journal of Pharmaceutical Education, 1(1), 40–46. https://doi.org/10.37311/ijpe.v1i1.9953
Riskesdas. (2018). Hasil Utama Riset Kesehata Dasar (RISKESDAS).
Sari, R. N. (2012). Diabtetes Mellitus. Nuha Medika.
Syamsiyah, N. (2017). Berdamai Dengan Diabetes T. B. Medika
Wicaksana. (2019). Analisis Biaya Rata-Rata Pasien Rawat Inap Dengan Penyakit Diabetes Mellitus Type Ii. Jurnal Lingkungan & Pembangunan, Oktober 2019, 3(2), 22–23.
World Health Organization., 2016., & WHO, G. R. on D. F. : (2016). Global Report On Diabetes. 88.
Yuswantina, R., & Dyahariesti, N. (2018). Analisis Efektivitas Biaya Penggunaan Antidiabetes Oral Tunggal dan Kombinasi Pada Pasien BPJS Penderita Diabetes Melitus Tipe 2 di Rumah Sakit X. Media Farmasi Indonesia, 13(1), 1340–1346.